All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Data due by the end of the year from the phase Ib trial testing Proteostasis Therapeutics Inc.'s cystic fibrosis (CF) prospect PTI-428 could trigger moves by developers in the space looking to pair the drug with therapies such as Orkambi (lumacaftor/ivacaftor) from Vertex Pharmaceuticals Inc.